A Phase 2 interventional study of BIC and F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-07.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the efficacy, safety and tolerability of bictegravir (BIC) + emtricitabine/tenofovir alafenamide (F/TAF) fixed dose combination (FDC) versus dolutegravir (DTG) + F/TAF in HIV-1 Infected, antiretroviral treatment-naive adults. This study will also evaluate the pharmacokinetic (PK) profile of BIC, emtricitabine and TAF.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive BIC + F/TAF FDC + DTG placebo for 48 weeks. * Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF.
Drug: BIC · Drug: F/TAF · Drug: DTG Placebo · Drug: B/F/TAF
Participants will receive DTG + F/TAF FDC + BIC placebo for 48 weeks. * Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive B/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF.
Drug: F/TAF · Drug: DTG · Drug: BIC Placebo · Drug: B/F/TAF
After Week 48 participants continued to take their randomized study drug and attended visits every 12 weeks until treatment assignments were unblinded, at which point all participants returned for an unblinding visit and were given the option to participate in an open-label rollover extension to receive an FDC containing B/F/TAF.
Drug: B/F/TAF
75 mg tablet administered orally once daily
Also known as: GS-9883
Drug pages: Emtricitabine · Tenofovir alafenamide
200/25 mg FDC tablet administered orally once daily
50 mg tablet administered orally once daily
Also known as: Tivicay®
Tablet administered orally once daily
Tablet administered orally once daily
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg FDC tablet administered orally once daily
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm.
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 12
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 12
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 48
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
The Change From Baseline in log10 HIV-1 RNA at Week 12
Time frame: Baseline; Week 12
The Change From Baseline in log10 HIV-1 RNA at Week 24
Time frame: Baseline; Week 24
The Change From Baseline in log10 HIV-1 RNA at Week 48
Time frame: Baseline; Week 48
The Change From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count at Week 12
Time frame: Baseline; Week 12
The Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline; Week 24
The Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) During Double-Blinded Randomized Phase
Time frame: First dose date up to last dose (maximum duration: 58 Weeks) plus 30 days (During Double-Blinded Randomized Phase)
Percentage of Participants With Treatment Emergent Laboratory Abnormalities During Double-Blind Randomized Phase
Time frame: First dose date up to last dose (maximum duration: 58 Weeks) plus 30 days (During Double-Blinded Randomized Phase)
PK Parameter: Cmax for Bictegravir (BIC), Emtricitabine (FTC), Tenofovir Alafenamide (TAF) and Tenofavir (TFV) at Steady-State
Cmax is the maximum observed plasma concentration of the drug.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
PK Parameter: Tmax for BIC, FTC, TAF, and TFV at Steady-State
Tmax was defined as the time to Cmax.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
PK Parameter:Ctau for BIC, FTC and TFV
Ctau was defined as the observed drug concentration at the end of the dosing interval.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
PK Parameter: AUCtau for BIC, FTC, TAF, and TFV
AUCtau is defined as the area under the concentration-time curve of the drug over time.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
PK Parameter: t1/2 of BIC, FTC, TAF, and TFV
t1/2 was defined as the terminal elimination half-life of the drug
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
Participants were enrolled at 22 centers in the United States of America.The first participant was screened on 23 March 2015 and the last study visit occurred on 27 February 2019.
| Milestone | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| Started | 65 | 33 |
| Completed | 62 | 30 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Milestone | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| Started | 62 | 30 |
| Completed | 54 | 29 |
| Not completed | 8 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrew consent | 3 | 1 |
| Withdrew: Lost to follow-up | 4 | 0 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm. | 96.9 | 93.9 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 12 | 93.8 | 93.9 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 48 | 96.9 | 90.9 |
| log10 copies/mL | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| The Change From Baseline in log10 HIV-1 RNA at Week 12 | -3.03 ± 0.791 | -3.15 ± 0.731 |
| log10 copies/mL | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| The Change From Baseline in log10 HIV-1 RNA at Week 24 | -3.09 ± 0.740 | -3.12 ± 0.757 |
| log10 copies/mL | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| The Change From Baseline in log10 HIV-1 RNA at Week 48 | -3.09 ± 0.752 | -3.11 ± 0.852 |
| CD4 Cell Count (/μL) | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| The Change From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count at Week 12 | 170 ± 150.0 | 173 ± 220.5 |
| CD4 Cell Count (/μL) | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| The Change From Baseline in CD4+ Cell Count at Week 24 | 190 ± 176.8 | 155 ± 165.8 |
| CD4 Cell Count (/μL) | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| The Change From Baseline in CD4+ Cell Count at Week 48 | 258 ± 221.7 | 188 ± 238.7 |
| percentage of participants | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) During Double-Blinded Randomized Phase | 87.7 | 72.7 |
| percentage of participants | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants With Treatment Emergent Laboratory Abnormalities During Double-Blind Randomized Phase | 87.5 | 87.5 |
Cmax is the maximum observed plasma concentration of the drug.
| ng/mL | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| BIC | 9344.3 ± 2506.33 | NA ± NA |
| FTC | 1919.1 ± 470.18 | 2157.1 ± 486.44 |
| TAF | 249.1 ± 137.40 | 260.8 ± 212.44 |
| TFV | 19.1 ± 4.50 | 20.9 ± 8.16 |
Tmax was defined as the time to Cmax.
| hours | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| BIC | 2.00 (1.50 to 3.00) | NA (NA to NA) |
| FTC | 1.50 (1.00 to 2.00) | 1.50 (1.02 to 2.00) |
| TAF | 1.00 (0.50 to 1.50) | 1.00 (0.50 to 1.00) |
| TFV | 1.50 (1.50 to 2.00) | 2.00 (1.53 to 2.00) |
Ctau was defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| BIC | 3508.6 ± 1288.85 | NA ± NA |
| FTC | 76.6 ± 26.35 | 102.6 ± 57.60 |
| TFV | 10.7 ± 2.65 | 12.2 ± 5.02 |
AUCtau is defined as the area under the concentration-time curve of the drug over time.
| h*ng/mL | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| BIC | 139778.8 ± 37810.07 | NA ± NA |
| FTC | 11605.4 ± 3241.84 | 14689.8 ± 5869.37 |
| TAF | 247.4 ± 140.62 | 245.6 ± 125.03 |
| TFV | 316.0 ± 74.01 | 369.4 ± 147.96 |
t1/2 was defined as the terminal elimination half-life of the drug
| hours | BIC + F/TAF | DTG + F/TAF |
|---|---|---|
| BIC | 16.73 (13.79 to 19.28) | NA (NA to NA) |
| FTC | 5.46 (5.19 to 6.11) | 5.70 (5.3 to 6.38) |
| TAF | 0.37 (0.28 to 0.49) | 0.42 (0.40 to 0.45) |
| TFV | 37.74 (28.26 to 48.40) | 34.47 (31.97 to 47.57) |
Collected over First dose date to last dose date of BIC + F/TAF or B/F/TAF (maximum duration: 193.4 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BIC + F/TAF (Double-Blind Randomized) | 0/65 (0%) | 4/65 (6.2%) | 44/65 (67.7%) |
| DTG + F/TAF (Double Blind Randomized): | 0/33 (0%) | 0/33 (0%) | 18/33 (54.5%) |
| BIC + F/TAF to B/F/TAF (Open-Label Phase) | 0/62 (0%) | 3/62 (4.8%) | 42/62 (67.7%) |
| DTG + F/TAF to B/F/TAF (Open-Label Phase) | 0/30 (0%) | 5/30 (16.7%) | 23/30 (76.7%) |
| Event | BIC + F/TAF (Double-Blind Randomized) | DTG + F/TAF (Double Blind Randomized): | BIC + F/TAF to B/F/TAF (Open-Label Phase) | DTG + F/TAF to B/F/TAF (Open-Label Phase) |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/65 | 0/33 | 0/62 | 1/30 |
| ColitisGastrointestinal disorders | 0/65 | 0/33 | 0/62 | 1/30 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/65 | 0/33 | 0/62 | 1/30 |
| Substance-induced psychotic disorderPsychiatric disorders | 0/65 | 0/33 | 0/62 | 1/30 |
| Suicide attemptPsychiatric disorders | 0/65 | 0/33 | 0/62 | 1/30 |
| Bladder massRenal and urinary disorders | 0/65 | 0/33 | 0/62 | 1/30 |
| PyelonephritisInfections and infestations | 0/65 | 0/33 | 1/62 | 0/30 |
| Rib fractureInjury, poisoning and procedural complications | 0/65 | 0/33 | 1/62 | 0/30 |
| Anal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/65 | 0/33 | 1/62 | 0/30 |
| Umbilical herniaGastrointestinal disorders | 1/65 | 0/33 | 0/62 | 0/30 |
| Event | BIC + F/TAF (Double-Blind Randomized) | DTG + F/TAF (Double Blind Randomized): | BIC + F/TAF to B/F/TAF (Open-Label Phase) | DTG + F/TAF to B/F/TAF (Open-Label Phase) |
|---|---|---|---|---|
| Proctitis gonococcalInfections and infestations | 1/65 | 1/33 | 2/62 | 5/30 |
| SyphilisInfections and infestations | 3/65 | 1/33 | 8/62 | 5/30 |
| DiarrhoeaGastrointestinal disorders | 9/65 | 4/33 | 4/62 | 4/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/65 | 1/33 | 7/62 | 0/30 |
| Upper respiratory tract infectionInfections and infestations | 7/65 | 1/33 | 4/62 | 1/30 |
| NauseaGastrointestinal disorders | 5/65 | 3/33 | 2/62 | 3/30 |
| BronchitisInfections and infestations | 2/65 | 0/33 | 2/62 | 3/30 |
| NasopharyngitisInfections and infestations | 3/65 | 1/33 | 3/62 | 3/30 |
| Exposure to communicable diseaseInjury, poisoning and procedural complications | 2/65 | 2/33 | 6/62 | 2/30 |
| HeadacheNervous system disorders | 6/65 | 1/33 | 0/62 | 1/30 |
The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | BIC + F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Mean | 34 ± 11.4 | 38 ± 12.9 | 35 ± 12.1 |
| Sex: Female, Male(Participants) | BIC + F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Female | 1 | 3 | 4 |
| Male | 64 | 30 | 94 |
| Race/Ethnicity, Customized(Participants) | BIC + F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 2 | 3 |
| Black | 24 | 12 | 36 |
| Native Hawaiian or Pacific Islander | 1 | 0 | 1 |
| White | 38 | 18 | 56 |
| Other | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | BIC + F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 4 | 15 |
| Not Hispanic or Latino | 54 | 29 | 83 |
| HIV-1 RNA(log10 copies/mL) | BIC + F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Mean | 4.39 ± 0.764 | 4.38 ± 0.866 | 4.39 ± 0.795 |
| HIV-1 RNA category(Participants) | BIC + F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| ≤ 100,000 copies/mL | 55 | 26 | 81 |
| > 100,000 to ≤ 400,000 copies/mL | 6 | 6 | 12 |
| > 400,000 copies/mL | 4 | 1 | 5 |
| CD4 Cell Count(cells/μL) | BIC + F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Mean | 471 ± 190.9 | 507 ± 271.0 | 483 ± 220.3 |
| CD4 Cell Count Category(Participants) | BIC + F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| < 200 cells/μL | 3 | 3 | 6 |
| ≥ 200 to < 350 cells/µL | 17 | 8 | 25 |
| ≥ 350 to < 500 cells/µL | 20 | 6 | 26 |
| ≥ 500 cells/µL | 25 | 16 | 41 |
Plan to share: No
Ran from Mar 2015 to primary completion in Nov 2015, 8 months.
Results were first posted in Mar 2018, 2 years 3 months after primary completion. A results delay was requested in Aug 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide